The nanoparticles are designed to deliver a therapeutic gene to the patient’s eye through a single intravenous injection, rather than through a series of injections given directly into the eye.
Dr. Ambati and his research team are currently testing the treatment on mice.
More Articles on Ophthalmology:
Dr. Gholman Peyman Joins Insite Vision
Durrie Vision Helps Develop SBK LASIK
National Eye Institute Funds $6.2M Macular Degeneration Study
